Medtronic Gets New FDA Approval For Heart Condition Treatment
13 Diciembre 2023 - 5:51PM
Noticias Dow Jones
By Sabela Ojea
Medtronic said the U.S. Food and Drug Administration has
approved its PulseSelect Pulsed Field Ablation System for the
treatment of two heart conditions.
The Dublin-based medical technology company on Wednesday said
the company's heart technology can now treat paroxysmal and
persistent atrial fibrillation following the FDA's approval.
Commercialization of the PulseSelect PFA system will start in
early 2024.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
December 13, 2023 18:36 ET (23:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Medtronic (NYSE:MDT)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Medtronic (NYSE:MDT)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
